Metagenomi Therapeutics (MGX) Stock Overview
An in vivo genome editing company, develops curative genetic medicines in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MGX Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Market Is Sleeping on This Parkinson's Biotech - And I Think That's a Mistake
Gain Therapeutics: The Under-the-Radar Biotech With Big Parkinson’s Potential Key Takeaways Gain Therapeutics (GANX) is developing GT-02287 – an oral, first-in-class, potentially disease-modifying treatment for Parkinson’s disease targeting the GCase enzyme pathway. Parkinson’s disease represents a $4 billion U.S. market with zero approved disease-modifying therapies.Read more
Metagenomi Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.53 |
| 52 Week High | US$3.95 |
| 52 Week Low | US$1.25 |
| Beta | 0.57 |
| 1 Month Change | 7.75% |
| 3 Month Change | -4.97% |
| 1 Year Change | -8.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -85.16% |
Recent News & Updates
Recent updates
Metagenomi, Inc.'s (NASDAQ:MGX) 26% Dip In Price Shows Sentiment Is Matching Revenues
Mar 16
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential
Jan 28The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26%
Jan 28We Think Metagenomi (NASDAQ:MGX) Needs To Drive Business Growth Carefully
Jan 14Metagenomi, Inc. (NASDAQ:MGX) Stock Catapults 106% Though Its Price And Business Still Lag The Industry
Dec 10Shareholder Returns
| MGX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 9.3% | 3.1% | 4.0% |
| 1Y | -8.4% | 44.7% | 38.7% |
Return vs Industry: MGX underperformed the US Biotechs industry which returned 44.7% over the past year.
Return vs Market: MGX underperformed the US Market which returned 38.7% over the past year.
Price Volatility
| MGX volatility | |
|---|---|
| MGX Average Weekly Movement | 8.6% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: MGX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MGX's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 119 | Jian Irish | metagenomi.co |
Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company’s lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyretin (TTR) for transthyretin amyloidosis, angiotensinogen (AGT) for refractory hypertension, and other programs.
Metagenomi Therapeutics, Inc. Fundamentals Summary
| MGX fundamental statistics | |
|---|---|
| Market cap | US$55.68m |
| Earnings (TTM) | -US$87.87m |
| Revenue (TTM) | US$25.21m |
Is MGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MGX income statement (TTM) | |
|---|---|
| Revenue | US$25.21m |
| Cost of Revenue | US$94.43m |
| Gross Profit | -US$69.22m |
| Other Expenses | US$18.65m |
| Earnings | -US$87.87m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.34 |
| Gross Margin | -274.59% |
| Net Profit Margin | -348.54% |
| Debt/Equity Ratio | 0% |
How did MGX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 01:47 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metagenomi Therapeutics, Inc. is covered by 5 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Maurice Raycroft | Jefferies LLC |
| Lut Ming Cheng | J.P. Morgan |